Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab.
The global Ranibizumab market was valued at US$ 3449.6 million in 2023 and is anticipated to reach US$ 1647.3 million by 2030, witnessing a CAGR of -9.9% during the forecast period 2024-2030.
Global core ranibizumab manufacturers include Roche and Novartis etc. The Top 2 companies hold a share about 98%. North America is the largest market, with a share about 51%, followed by Europe and Asia Pacific with the share about 28% and 20%.
This report aims to provide a comprehensive presentation of the global market for Ranibizumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ranibizumab.
Report Scope
The Ranibizumab market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ranibizumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ranibizumab companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
Segment by Type
Glass Vial
Prefilled Syringe
Segment by Application
Wet AMD
Complications of Diabetes
RVO
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ranibizumab companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ranibizumab Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Glass Vial
1.2.3 Prefilled Syringe
1.3 Market by Application
1.3.1 Global Ranibizumab Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Wet AMD
1.3.3 Complications of Diabetes
1.3.4 RVO
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ranibizumab Market Perspective (2019-2030)
2.2 Ranibizumab Growth Trends by Region
2.2.1 Global Ranibizumab Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Ranibizumab Historic Market Size by Region (2019-2024)
2.2.3 Ranibizumab Forecasted Market Size by Region (2025-2030)
2.3 Ranibizumab Market Dynamics
2.3.1 Ranibizumab Industry Trends
2.3.2 Ranibizumab Market Drivers
2.3.3 Ranibizumab Market Challenges
2.3.4 Ranibizumab Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ranibizumab Players by Revenue
3.1.1 Global Top Ranibizumab Players by Revenue (2019-2024)
3.1.2 Global Ranibizumab Revenue Market Share by Players (2019-2024)
3.2 Global Ranibizumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ranibizumab Revenue
3.4 Global Ranibizumab Market Concentration Ratio
3.4.1 Global Ranibizumab Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ranibizumab Revenue in 2023
3.5 Ranibizumab Key Players Head office and Area Served
3.6 Key Players Ranibizumab Product Solution and Service
3.7 Date of Enter into Ranibizumab Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ranibizumab Breakdown Data by Type
4.1 Global Ranibizumab Historic Market Size by Type (2019-2024)
4.2 Global Ranibizumab Forecasted Market Size by Type (2025-2030)
5 Ranibizumab Breakdown Data by Application
5.1 Global Ranibizumab Historic Market Size by Application (2019-2024)
5.2 Global Ranibizumab Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Ranibizumab Market Size (2019-2030)
6.2 North America Ranibizumab Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Ranibizumab Market Size by Country (2019-2024)
6.4 North America Ranibizumab Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ranibizumab Market Size (2019-2030)
7.2 Europe Ranibizumab Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Ranibizumab Market Size by Country (2019-2024)
7.4 Europe Ranibizumab Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ranibizumab Market Size (2019-2030)
8.2 Asia-Pacific Ranibizumab Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Ranibizumab Market Size by Region (2019-2024)
8.4 Asia-Pacific Ranibizumab Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ranibizumab Market Size (2019-2030)
9.2 Latin America Ranibizumab Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Ranibizumab Market Size by Country (2019-2024)
9.4 Latin America Ranibizumab Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ranibizumab Market Size (2019-2030)
10.2 Middle East & Africa Ranibizumab Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Ranibizumab Market Size by Country (2019-2024)
10.4 Middle East & Africa Ranibizumab Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Ranibizumab Introduction
11.1.4 Roche Revenue in Ranibizumab Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Ranibizumab Introduction
11.2.4 Novartis Revenue in Ranibizumab Business (2019-2024)
11.2.5 Novartis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Roche
Novartis
*If Applicable.